{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:07:14Z","timestamp":1792465634589,"version":"4.5.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world data on the vaccine effectiveness (VE) of the adjuvanted recombinant zoster vaccine (RZV) to prevent herpes zoster (HZ) among individuals with autoimmune diseases (AIDs) are limited. To address this knowledge gap, we aimed to evaluate the VE of 2 RZV doses against HZ in \u226550-year-old adults with selected AIDs (rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis (MS), psoriasis (PsO), and psoriatic arthritis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective matched cohort study using Optum's deidentified Clinformatics\u00ae Data Mart Database datasets from January 2018 to December 2021. Patients were matched by AID condition, age, and medication category, then 1:3 by propensity scores that accounted for the likelihood of receiving RZV, adjusted on selected confounders. For each AID, we calculated HZ incidence rates and RZV VE, overall and stratified by age, sex, time interval between 2 RZV doses, medication category, and time since vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 2-dose cohort included 36 645 RZV-vaccinated and 109 229 unvaccinated patients. Two RZV doses offer protection against HZ in patients with AIDs, with VEs ranging from 48.1% for MS to 77.2% for PsO. An overall reduction in HZ incidence from 12.9 (95% confidence interval [CI]: 12.3; 13.5) to 4.3 (95% CI: 3.8; 4.9) per 1000 person-years among vaccinated individuals was found, corresponding to an overall VE against HZ of 66.3% (95% CI: 61.4; 70.7).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our analysis shows that RZV vaccination prevents HZ in \u226550-year-old adults with selected AIDs, consistent with prior studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf395","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T12:06:50Z","timestamp":1754654810000},"page":"e931-e940","source":"Crossref","is-referenced-by-count":12,"title":["Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in \u226550-year-old Adults With Autoimmune Diseases"],"prefix":"10.1093","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4935-1584","authenticated-orcid":false,"given":"Dagna","family":"Constenla","sequence":"first","affiliation":[{"name":"GSK , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germain","family":"Lonnet","sequence":"additional","affiliation":[{"name":"GSK , Wavre ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8640-1742","authenticated-orcid":false,"given":"Emmanuel","family":"Aris","sequence":"additional","affiliation":[{"name":"GSK , Wavre ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8857-460X","authenticated-orcid":false,"given":"Ramsanjay","family":"Rk","sequence":"additional","affiliation":[{"name":"GSK , Bengaluru, Karnataka ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Servotte","sequence":"additional","affiliation":[{"name":"GSK , Wavre ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Mwakingwe-Omari","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9801-7852","authenticated-orcid":false,"given":"Hannah","family":"Alsdurf","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0158-1797","authenticated-orcid":false,"given":"Huifeng","family":"Yun","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"2026031304475705200_jiaf395-B1","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"2026031304475705200_jiaf395-B2","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.cgh.2017.12.052","article-title":"Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study","volume":"16","author":"Khan","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026031304475705200_jiaf395-B3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/apt.12182","article-title":"Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease","volume":"37","author":"Long","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2026031304475705200_jiaf395-B4","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2026031304475705200_jiaf395-B5","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026031304475705200_jiaf395-B6","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","article-title":"Risk factors for herpes zoster: a systematic review and meta-analysis","volume":"92","author":"Kawai","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2026031304475705200_jiaf395-B7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jaad.2019.03.017","article-title":"A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: from the Medical Board of the National Psoriasis Foundation","volume":"81","author":"Baumrin","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2026031304475705200_jiaf395-B8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","article-title":"Incidence of herpes zoster in patients with altered immune function","volume":"42","author":"Chen","year":"2014","journal-title":"Infection"},{"key":"2026031304475705200_jiaf395-B9","doi-asserted-by":"crossref","first-page":"e0179447","DOI":"10.1371\/journal.pone.0179447","article-title":"Increased risk of herpes zoster in patients with psoriasis: a population-based retrospective cohort study","volume":"12","author":"Tsai","year":"2017","journal-title":"PLoS One"},{"key":"2026031304475705200_jiaf395-B10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/RHU.0b013e3181d52ed7","article-title":"Incidence, risk factors, and outcome of Herpes zoster in systemic lupus erythematosus","volume":"16","author":"Borba","year":"2010","journal-title":"J Clin Rheumatol"},{"key":"2026031304475705200_jiaf395-B11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026031304475705200_jiaf395-B12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026031304475705200_jiaf395-B13","author":"FDA"},{"key":"2026031304475705200_jiaf395-B14","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"2026031304475705200_jiaf395-B15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"2026031304475705200_jiaf395-B16","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/rheumatology\/keaa424","article-title":"Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials","volume":"60","author":"Dagnew","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026031304475705200_jiaf395-B17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"2026031304475705200_jiaf395-B18","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2026031304475705200_jiaf395-B19","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026031304475705200_jiaf395-B20","author":"Optum\u00ae"},{"key":"2026031304475705200_jiaf395-B21","doi-asserted-by":"crossref","first-page":"ofw205","DOI":"10.1093\/ofid\/ofw205","article-title":"Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and\/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis","volume":"3","author":"Marra","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2026031304475705200_jiaf395-B22","doi-asserted-by":"crossref","first-page":"ofaa005","DOI":"10.1093\/ofid\/ofaa005","article-title":"Risk factors for herpes zoster infection: a meta-analysis","volume":"7","author":"Marra","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026031304475705200_jiaf395-B23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3949\/ccjm.91a.24019","article-title":"Preventing herpes zoster in immunocompromised patients: current concepts","volume":"91","author":"Calabrese","year":"2024","journal-title":"Cleve Clin J Med"},{"key":"2026031304475705200_jiaf395-B24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/pds.3447","article-title":"Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009","volume":"22","author":"Asgari","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026031304475705200_jiaf395-B25","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/oxfordjournals.aje.a009735","article-title":"Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study","volume":"149","author":"Bernstein","year":"1999","journal-title":"Am J Epidemiol"},{"key":"2026031304475705200_jiaf395-B26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrrheum.2014.15","article-title":"Diagnosis and management of neuropsychiatric SLE","volume":"10","author":"Hanly","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"2026031304475705200_jiaf395-B27","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.284.8.984","article-title":"Quality of care for patients with rheumatoid arthritis","volume":"284","author":"MacLean","year":"2000","journal-title":"JAMA"},{"key":"2026031304475705200_jiaf395-B28","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/03007995.2020.1771293","article-title":"Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population","volume":"36","author":"Pilon","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"2026031304475705200_jiaf395-B29","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/ajg.2011.304","article-title":"Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis","volume":"106","author":"Shaw","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2026031304475705200_jiaf395-B30","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"},{"key":"2026031304475705200_jiaf395-B31","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1572-0241.2007.01215.x","article-title":"Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern California-managed care organization","volume":"102","author":"Weng","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"2026031304475705200_jiaf395-B32","author":"CDC"},{"key":"2026031304475705200_jiaf395-B33","article-title":"Vaccine effectiveness and safety of recombinant zoster vaccine (RZV) in rheumatoid arthritis (RA) patient populations aged 50 years and older [abstract]","volume":"76","author":"Rayens","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026031304475705200_jiaf395-B34","doi-asserted-by":"crossref","first-page":"ofae631.224","DOI":"10.1093\/ofid\/ofae631.224","article-title":"P-14. Vaccine effectiveness and safety of recombinant zoster vaccine in inflammatory bowel disease patient populations aged 50 years and older","volume":"12","author":"Rayens","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026031304475705200_jiaf395-B35","doi-asserted-by":"crossref","first-page":"2263979","DOI":"10.1080\/21645515.2023.2263979","article-title":"Effectiveness and safety of recombinant zoster vaccine: a review of real-world evidence","volume":"19","author":"Parikh","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"2026031304475705200_jiaf395-B36","article-title":"Effectiveness and safety of the recombinant zoster vaccine in patients \u226518 years of age with systemic lupus erythematosus or multiple sclerosis [abstract]","volume":"76","author":"Kluberg","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026031304475705200_jiaf395-B37","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1016\/j.vaccine.2021.05.056","article-title":"Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: a retrospective cohort study","volume":"39","author":"Sun","year":"2021","journal-title":"Vaccine"},{"key":"2026031304475705200_jiaf395-B38","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/ibd\/izy150","article-title":"Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention","volume":"24","author":"Colombel","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026031304475705200_jiaf395-B39","doi-asserted-by":"crossref","first-page":"978203","DOI":"10.3389\/fimmu.2022.978203","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: a systematic review and network meta-analysis","volume":"13","author":"Xia","year":"2022","journal-title":"Front Immunol"},{"key":"2026031304475705200_jiaf395-B40","doi-asserted-by":"crossref","first-page":"ofac485","DOI":"10.1093\/ofid\/ofac485","article-title":"Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination","volume":"9","author":"Strezova","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026031304475705200_jiaf395-B41","author":"FDA"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf395\/63999589\/jiaf395.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/6\/e931\/63999589\/jiaf395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/6\/e931\/63999589\/jiaf395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:48:20Z","timestamp":1773391700000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/6\/e931\/8230148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,8,11]]},"published-print":{"date-parts":[[2025,12,20]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf395","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,15]]},"published":{"date-parts":[[2025,8,11]]}}}